Ovsyscher I E, Katz A, Rosenheck S, Erdman S, Bondy C
Arrhythmia Service, Soroka Medical Center, Beer-Sheva, Israel.
Pacing Clin Electrophysiol. 1996 Nov;19(11 Pt 2):1768-71. doi: 10.1111/j.1540-8159.1996.tb03221.x.
Optimal treatment for patients with AV block and normal sinoatrial node (SA) function entails atrial sensing and ventricular pacing (VDD mode). Single-lead VDD pacing preserves AV synchrony, precludes the need to insert two leads, and makes the implanter's work simpler and quicker. Our objectives were to verify the performance of the Thera VDD pacing system (medtronic, Inc., Minneapolis, MN, USA), and evaluate the effectiveness of its atrial sensing and its ventricular sensing and pacing. In 165 patients, 150 adults (mean age 62 +/- 18 years) and 15 children (mean age 7 +/- 5 years) with 1 degree-3 degrees AV block and normal SA node function, a Thera VDD system (Models 8948 or 8968) was implanted. Intraoperative ventricular electrical measurements were not significantly different from those of VVI pacemakers. The mean amplitude of the atrial signal during implantation was 4.1 +/- 1.9 mV. Optimal atrial signals during implantation were usually obtained in the mid or lower part of the right atrium by using a special technique. Adequate atrial measurements remained stable throughout 24 months. There was no difference between serial measurements of atrial signal amplitudes at predischarge and during follow-up visits. Reposition of the lead was done in 2 patients (1.4%), and reprogramming to VVI in 7 patients: due to atrial fibrillation in 3 (1.8%) and due to atrial undersensing in 4 patients (2.4%). Thera VDD pacing is reliable and easy to manage with dependable atrial sensing and ventricular pacing. The survival rate of VDD pacing at 2 years was 96%.
对于房室传导阻滞且窦房结(SA)功能正常的患者,最佳治疗方法是心房感知和心室起搏(VDD模式)。单导联VDD起搏可保持房室同步,无需插入两根导联,使植入者的工作更简单、快捷。我们的目的是验证Thera VDD起搏系统(美敦力公司,美国明尼苏达州明尼阿波利斯)的性能,并评估其心房感知、心室感知及起搏的有效性。在165例患者中,150例为成年人(平均年龄62±18岁),15例为儿童(平均年龄7±5岁),均患有一度至三度房室传导阻滞且窦房结功能正常,植入了Thera VDD系统(8948或8968型号)。术中心室电测量结果与VVI起搏器的测量结果无显著差异。植入期间心房信号的平均振幅为4.1±1.9 mV。植入期间通过一种特殊技术通常可在右心房中部或下部获得最佳心房信号。在整个24个月中,足够的心房测量值保持稳定。出院前和随访期间心房信号振幅的系列测量结果无差异。2例患者(1.4%)进行了导线重新定位,7例患者重新编程为VVI模式:3例(1.8%)是由于房颤,4例(2.4%)是由于心房感知不足。Thera VDD起搏可靠且易于管理,心房感知和心室起搏可靠。VDD起搏2年生存率为96%。